BioSpace News Archive

Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced it has acquired the On.Demand™ remote patient monitoring (RPM) and coaching platform, operated by Envolve People Care, Inc., a Centene Corporation subsidiary. This acquisition adds chronic RPM and coaching solutions to BioTelemetry’s current suite of acut

Chief Operating Officer Kurt Becker to Take on Broadened Role Overseeing Global Operations and Research and Development

Trobix Innovation Ltd. ( Trobix Bio ), an Israeli-based biotechnology company developing therapies to remove the threat of antimicrobial resistance, announces the closing of a US $ 3 Million Series A funding from its lead investor, Chartered Opus . The funding will be used to advance the company’s antimicrobial resistance platform

Rigorously and independently tested and validated, Easy Check exceeds current testing requirements for the detection of IgM/IgG antibodies to SARS-CoV-2

Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care, today announced completion of the first worldwide commercial case using the TriGUARD 3™ Cerebral Embolic Protection (CEP) Device.

Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to RGLS4326 for the treatment of patients

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced Otsuka Pharmaceutical Co., Ltd. has submitted an application to the Pharmaceuticals and Medical Devices Agency of Japan to obtain manufacturing and marketing approval in Japan for AJOVY ® (fremanezumab) injection for the preventive treatment of migraine.

IQVIA™ (NYSE: IQV) today introduced OCE Optimizer , an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s Orchestrated Customer Engagement solution by intelligently allocating

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s chief scientific officer and co-founder, will participate in a fireside chat hosted by LifeSci Capital on Thursday, July 30 at 3:00 p.m. EDT